Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Development and Approval : Small Molecules: The pathway for development and regulatory approval is well-established, with clear guidelines for demonstrating safety and efficacy.

Development 81

Development Drugs Manufacturing Immune Response 81

Pharmaceutical Technology

AUGUST 17, 2022

Biopharmaceutical contract development and manufacturing organisation (CDMO) AGC Biologics has entered a strategic collaboration with RoosterBio to expedite the manufacturing of cell and exosome therapies. These capabilities comprise cell and exosome genetic engineering for expressing therapeutic targets.

Manufacturing 130

Manufacturing Gene Therapy Genetic Engineering Gene 130

Pharmaceutical Technology

MAY 2, 2023

Chimeric antigen receptor T-cell (CAR-T) therapies are the only genetically modified cell therapies to have received regulatory approval, and they are currently utilised in relapsed/refractory settings. There is currently a rich and diverse IO pipeline that aims to address these unmet needs, with 703 IO products currently in clinical trials.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

Drug Discovery World

MAY 23, 2024

The three-year survival rate for children with high-grade gliomas, without further complications, is only 11-22%, and the currently available treatments, radiotherapy and chemotherapy, can harm the child’s developing brain. The researchers will use a genetically engineered herpes simplex virus type 1 to eliminate cancer cells.

Genetic Engineering 59

Genetic Engineering Engineer Immune Response Vaccination 59

pharmaphorum

NOVEMBER 6, 2020

Novartis’ Ilaris (canakinumab) has failed to produce results in a phase 3 trial, which tested whether it could improve COVID-19 patients’ survival chances without need for mechanical ventilation. The key secondary endpoint was to reduce the COVID-19-related death rate during the four week period after trial treatment.

Trials 40

Trials Genetic Engineering Licensing Licensing 40

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Two of the three planned late-stage efficacy trials for NVX-CoV2373 sponsored by Novavax are fully enrolled, and more than 20,000 participants have been dosed to-date.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Pharmaceutical Technology

JUNE 29, 2022

In September 2021, GlobalData figures revealed there to be 1,320 industry-sponsored regenerative medicine and advanced therapy trials ongoing worldwide. Developing best-in-class speciality enzymes. Novozymes has a long legacy of enzyme discovery and the ability to genetically engineer these speciality enzymes to be superior.

Drugs 295

Drugs Gene Therapy Manufacturing Production 295

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials.

Engineer 52

Engineer Genetics Clinical Research Research 52

Drug Discovery World

OCTOBER 4, 2022

With winter around the corner and cases once again on the rise, the last few weeks have seen some interesting developments related to Covid-19. A new study has provided the first detailed genetic insights into the pathophysiological mechanisms underpinning Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). .

Genetic Engineering 52

Genetic Engineering Genetics Engineer Drugs 52

XTalks

NOVEMBER 23, 2020

Severe cases of the infection did not occur among trial participants, nor were any hospitalizations reported. The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

NY Times

FEBRUARY 22, 2021

Two patients in a gene therapy study developed cancer years after treatment. It is not clear whether the therapy was responsible.

Gene Therapy 54

Gene Therapy Trials Research Gene 54

XTalks

MARCH 28, 2024

Colorectal Cancer: Advances in Treatment Options In recent years, there has been considerable progress in understanding the biology of CRC, which has helped develop more effective and personalized treatment options. An overview of some of the most promising developments in CRC treatment is provided below.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

Pharmaceutical Technology

APRIL 5, 2023

This includes the first potential approval of a CRISPR-based gene therapy called exa-cel , which is developed by CRISPR Therapeutics and Vertex Pharmaceuticals. And my estimate is that between 25,000 and 30,000 patients have been treated with those therapies globally, which does not include patients treated in clinical trials.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

pharmaphorum

FEBRUARY 18, 2021

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

Bioengineer

JULY 21, 2021

Researchers have proposed a new scoring system for wound healing in mice based on parameters in each phase of healing, as described in an article in the peer-reviewed journal Stem Cells and Development. Mari van de Vyver, from Stellenbosch University, and colleagues developed this histology scoring system for murine cutaneous wounds.

Genetic Engineering 52

Genetic Engineering Development Engineer Genetics 52

WCG Clinical

MAY 28, 2024

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies. WCG has many ways to support cell and gene therapy clinical trials for lupus.

In-Vivo 52

In-Vivo Clinical Trials Clinical Trials FDA Approval 52

XTalks

MARCH 6, 2024

This includes discussions on cutting-edge technologies and methodologies in brain research, such as neuroimaging, genetic engineering and artificial intelligence. Lilly is currently conducting a Phase III trial evaluating its beta-amyloid targeting monoclonal antibody, donanemab.

FDA Approval 69

FDA Approval In-Vitro Research Marketing 69

The Pharma Data

NOVEMBER 9, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. “The

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Bioengineer

JULY 19, 2021

The development of KRAS inhibitors is, thus, an extremely active line of research. ” KRAS genes in embryonic development. The researchers at the CNIO created two genetically engineered mouse models that lacked KRAS4B and expressed the KRAS4A variant only, both with and without the G12V mutation (KRAS4AG12V).

Research 52

Research Gene Genetic Engineering Genetics 52

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent? MG: I am responsible for Agilent’s cancer segment.

Research 98

Research Protein Scientist Immune Response 98

XTalks

JULY 31, 2020

The study developed and researched microbe-controlled and genetically-engineered mice to understand the healing response in the intestine when receiving specific signals from bacteria. If we can influence these interactions, we may be able to control many diseases that are impacted by our microbiome or diet,” she says.

Bacteria 98

Bacteria Genetic Engineering Engineer Research 98

Bioengineer

JULY 15, 2021

“The first step in developing leadership skills requires introspection and contemplation,” she says. She guides nurses through the development of a Personal Professional Philosophy Statement, which should have two components: one’s core beliefs and values; and the values of the profession. ” ###. liebertpub.

Nurses 52

Nurses Genetic Engineering Engineer Genetics 52

The Pharma Data

OCTOBER 27, 2020

28, 2020 /PRNewswire/ — Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces the formation of a new Scientific Advisory Board (SAB). OSLO, Norway , Oct. Fennel cover the key scientific focus areas of Targovax. Dean A.

Antibody 52

Antibody Genetic Engineering Engineer Development 52

The Pharma Data

DECEMBER 16, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 NVX-CoV2373 is being evaluated in an ongoing Phase 3 trial in the U.K. GAITHERSBURG, Md., and Australia.

Protein 52

Protein Vaccination Vaccine Immune Response 52

The Pharma Data

MARCH 29, 2022

Published today in Nature, the research opens the door to developing a therapeutic spray for humans. The small molecule was developed by Drs. ” The project teams are working with Ebvia, a private company, to secure funding for clinical trials. 2 around the world.”

Genetic Engineering 52

Genetic Engineering Research Genetics Drugs 52

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. SAN JOSE, Calif. , About Aridis Pharmaceuticals, Inc.

Antibody 52

Antibody Genetic Engineering Development Licensing 52

The Pharma Data

JULY 27, 2021

Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. executive vice president of Research and Development at Amgen. billion in cash. Reese, M.D.,

Production 52

Production Antibody Sales Manufacturing 52

Drug Discovery World

NOVEMBER 17, 2022

The rapidly growing area of synthetic biology – including molecular biology, biotechnology, biophysics, and genetic engineering – is having a marked impact on the drug discovery landscape. However, the development of drugs takes decades which is too long for most biotech start- ups looking for fast-track drug development programs.

Bacteria 52

Bacteria Engineer Gene Genetics 52

The Pharma Data

APRIL 27, 2023

It is also an off-the-shelf therapy, meaning that people do not have to wait for cell collection and genetic engineering before starting treatment, which could be particularly important for patients who are at a high-risk of their disease progressing. Roche’s Chief Medical Officer and Head of Global Product Development.

Genetic Engineering 40

Genetic Engineering Clinical Development Antibody Medicine 40

The Pharma Data

SEPTEMBER 8, 2020

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

— Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Pharmaceutical Technology

SEPTEMBER 5, 2022

In March last year, CanSinoBIO obtained approval for the clinical trial application to analyse Convidecia Air. CNBC reported in April last year that the vaccine is being developed by the company in partnership with the Beijing Institute of Biotechnology (BIB).

Vaccination 264

Vaccination Vaccine Genetic Engineering Clinical Trials 264

Advarra

AUGUST 10, 2023

Gene therapy has achieved notable successes, particularly in treating resistant or refractory B cell leukemias (achieving overall response rates around 90% or greater) and the speed with which COVID-19 vaccines were developed under the original Operation Warp Speed. Why Warp Speed for Rare Diseases? What is the FDA Proposing to do?

Gene Therapy 52

Gene Therapy Development Gene Drugs 52

Drug Discovery World

JULY 22, 2022

For example, in randomised clinical trials of patients with non-small cell lung cancer (NSCLC), pembrolizumab has been shown to be effective in slowing down disease progression and improving survival rates 1. However, adverse effects such as cytokine release syndrome (CRS) and neurotoxicity still occur.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

JANUARY 10, 2022

There are still licensing deals to be done in the COVID-19 category it seems, after Novartis paid around $163 million to license rights to an antiviral drug developed by Molecular Partners. The post After trial win, Novartis nabs COVID drug from Molecular Partners appeared first on.

Trials 52

Trials Drugs Antibody Genetic Engineering 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130